Bronchodilator
Pregnancy: C — inhaled ICS considered safe in pregnancy; formoterol limited data
Budesonide / Formoterol
Brand names: Symbicort, DuoResp Spiromax, Fobumix
Adult dose
Dose: MART (asthma): 200/6mcg 1 puff BD maintenance + PRN (max 8 puffs/day). COPD: 400/12mcg BD
Route: Inhaled
Frequency: Twice daily (maintenance); PRN (reliever in MART strategy)
Max: 8 puffs/day (MART strategy Symbicort 200/6)
Budesonide/formoterol MART: single inhaler used for both maintenance and reliever. NICE recommends MART for moderate-severe asthma. COPD: 400/12 BD as add-on to LAMA.
Paediatric dose
Route: Inhaled
Frequency: Twice daily
Max: 4 puffs/day
Age bands
- 72–216m: 100/6mcg 1–2 puffs BD (children ≥6 years)
Clinical pearls
- MART strategy (maintenance and reliever therapy): single Symbicort 200/6 inhaler for both maintenance (1 puff BD) and symptom relief (additional puffs up to 8/day total). Reduces asthma attacks vs traditional fixed-dose regimen.
- Always prescribe with spacer if patient struggles with inhaler technique — equally effective to nebulised in acute moderate asthma.
- ICS component reduces eosinophilic airway inflammation. Formoterol is fast-acting LABA (onset 1–3 min vs salmeterol 15 min) — enabling reliever use.
- Rinse mouth and gargle after every dose — oral candidiasis prevention.
Contraindications
- Not for acute bronchospasm (formoterol onset ~3 min, use salbutamol if urgent)
- Hypersensitivity to budesonide or formoterol
Side effects
- Oral candidiasis (ICS component — use spacer, rinse mouth after each dose)
- Dysphonia / hoarseness (ICS component)
- Tachycardia, tremor (formoterol component — lower than salbutamol)
- HPA axis suppression (high-dose ICS — rare at licensed doses)
- Hypokalaemia at high doses
Interactions
- Beta-blockers: antagonise bronchodilator effect
- QT-prolonging drugs: additive risk with formoterol (dose-related)
- CYP3A4 inhibitors (ketoconazole): modestly increase budesonide levels
Monitoring
- Peak flow / FEV₁
- symptom diary
- exacerbation frequency
- inhaler technique
- oral cavity
Reference: BNFc; BTS/SIGN Asthma 2023; NICE NG80 Asthma; NICE BNF 84. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
Pathways
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024